MCID: ANT024
MIFTS: 57

Anthrax Disease

Categories: Infectious diseases, Rare diseases

Aliases & Classifications for Anthrax Disease

MalaCards integrated aliases for Anthrax Disease:

Name: Anthrax Disease 12 15 73
Anthrax 76 53 55 43 3 44
Ragpicker's Disease 53 73
Wool Sorter's Disease 53
Cutaneous Anthrax 73
Malignant Pustule 53
Malignant Edema 53
Siberian Plague 53
Gas Gangrene 73
Black Baine 53

Classifications:



External Ids:

Disease Ontology 12 DOID:7427
ICD10 33 A22 A22.9
ICD9CM 35 022 022.9
MeSH 44 D000881
NCIt 50 C84565
SNOMED-CT 68 17540007

Summaries for Anthrax Disease

NIH Rare Diseases : 53 Anthrax is an infection caused by the bacterium Bacillus anthracis. The severity of the condition, the associated signs and symptoms and the prognosis vary depending on which part of the body is involved (see below). Antibiotics can be used to treat all forms of anthrax. Antitoxin medications may also be used to treat some forms of the condition. Cutaneous (skin) anthrax occurs when the infection enters the body through a cut or sore on the skin. It is the most common type of anthrax and generally the least serious. Affected people may experience a group of small, itchy bumps; swelling around a sore; and/or a painless ulcer with a black center. These skin abnormalities are generally found on the face, neck, arms, or hands. With appropriate treatment, cutaneous anthrax is seldom fatal. Gastrointestinal anthrax is caused by eating undercooked meat from an infected animal. Signs and symptoms may include nausea, vomiting, abdominal pain, headache, loss of appetite, fever, and a sore throat. Pulmonary (lung) anthrax occurs when anthrax spores are inhaled. It is the most deadly form of the condition. Early signs include flu-like symptoms, shortness of breath, nausea, and coughing up blood. As the condition advances, affected people may develop high fever, difficulty breathing, shock, and meningitis. Even with treatment, pulmonary anthrax may be fatal.Injection anthrax is spread by injecting illegal drugs. Signs and symptoms of this form of anthrax include redness and swelling at the sight of the infection. The condition may progress to shock, multiple organ failure and meningitis.

MalaCards based summary : Anthrax Disease, also known as anthrax, is related to inhalation anthrax and cutaneous anthrax, and has symptoms including skin ulcer, nausea and poor appetite. An important gene associated with Anthrax Disease is ANTXR1 (ANTXR Cell Adhesion Molecule 1), and among its related pathways/superpathways are Toll-like Receptor Signaling Pathway and Influenza A. The drugs Diphenhydramine and Promethazine have been mentioned in the context of this disorder. Affiliated tissues include lung, skin and lymph node, and related phenotypes are Increased transferrin (TF) endocytosis and cardiovascular system

Disease Ontology : 12 A primary bacterial infectious disease that results in infection located in skin, located in lung lymph nodes or located in gastrointestinal tract, has material basis in Bacillus anthracis, transmitted by contact with infected animals or animal products, transmitted by airborne spores or transmitted by ingestion of undercooked meat from infected animals and has symptom skin ulcer, has symptom nausea, has symptom poor appetite, has symptom bloody diarrhea, has symptom fever or has symptom shortness of breath.

MedlinePlus : 43 Anthrax is a disease caused by Bacillus anthracis, a germ that lives in soil. Many people know about it from the 2001 bioterror attacks. In the attacks, someone purposely spread anthrax through the U.S. mail. This killed five people and made 22 sick. Anthrax is rare. It affects animals such as cattle, sheep, and goats more often than people. People can get anthrax from contact with infected animals, wool, meat, or hides. It can cause three forms of disease in people. They are Cutaneous, which affects the skin. People with cuts or open sores can get it if they touch the bacteria. Inhalation, which affects the lungs. You can get this if you breathe in spores of the bacteria. Gastrointestinal, which affects the digestive system. You can get it by eating infected meat. Antibiotics often cure anthrax if it is diagnosed early. But many people don't know they have anthrax until it is too late to treat. A vaccine to prevent anthrax is available for people in the military and others at high risk. NIH: National Institute of Allergy and Infectious Diseases

CDC : 3 SymptomsWho is at Risk of Exposure

Wikipedia : 76 Anthrax is an infection caused by the bacterium Bacillus anthracis. It can occur in four forms: skin,... more...

Related Diseases for Anthrax Disease

Diseases related to Anthrax Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 87)
# Related Disease Score Top Affiliating Genes
1 inhalation anthrax 32.4 ANTXR1 ANTXR2 TLR9
2 cutaneous anthrax 31.5 CASP1 PRDX1
3 oropharyngeal anthrax 12.4
4 gapo syndrome 11.1
5 gastrointestinal anthrax 11.0
6 plague 10.4
7 influenza 10.3
8 smallpox 10.3
9 tularemia 10.2
10 meningitis 10.2
11 pancreatic ductal adenocarcinoma 10.2
12 meningoencephalitis 10.2
13 adamantinoma of long bones 10.1
14 cholera 10.1
15 spondyloarthropathy 1 10.0
16 hepatitis 10.0
17 hepatitis b 10.0
18 pneumonia 10.0
19 spondylitis 10.0
20 vasculitis 10.0
21 hyaline fibromatosis syndrome 9.9
22 body mass index quantitative trait locus 1 9.9
23 cicatricial ectropion 9.9
24 glanders 9.9
25 ectropion 9.9
26 melanoma 9.9
27 cellulitis 9.9
28 compartment syndrome 9.9
29 venezuelan equine encephalitis 9.9
30 encephalitis 9.9
31 lymphocytic vasculitis 9.9
32 cerebral amyloid angiopathy, itm2b-related, 1 9.8 FURIN PCSK6
33 hepatocellular carcinoma 9.8
34 systemic lupus erythematosus 9.8
35 rheumatoid arthritis 9.8
36 tetralogy of fallot 9.8
37 3-methylglutaconic aciduria, type iii 9.8
38 leukemia, acute myeloid 9.8
39 late-onset retinal degeneration 9.8
40 severe cutaneous adverse reaction 9.8
41 granulomatosis with polyangiitis 9.8
42 microcephaly, epilepsy, and diabetes syndrome 9.8
43 arthritis 9.8
44 diabetes mellitus 9.8
45 hemolytic anemia 9.8
46 leukemia 9.8
47 erythema multiforme 9.8
48 variola major 9.8
49 tooth agenesis 9.8
50 pneumonic plague 9.8

Graphical network of the top 20 diseases related to Anthrax Disease:



Diseases related to Anthrax Disease

Symptoms & Phenotypes for Anthrax Disease

Symptoms:

12
  • skin ulcer
  • nausea
  • poor appetite
  • bloody diarrhea
  • fever or has_symptom shortness of breath

UMLS symptoms related to Anthrax Disease:


fever, pruritus

GenomeRNAi Phenotypes related to Anthrax Disease according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased transferrin (TF) endocytosis GR00363-A 9.17 ANTXR1 ANTXR2 CASP1 FURIN MAP2K2 PCSK6

MGI Mouse Phenotypes related to Anthrax Disease:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 9.91 ANTXR1 ANTXR2 CASP1 FURIN MAP2K2 MKKS
2 cellular MP:0005384 9.87 ANTXR1 ANTXR2 CASP1 MAP2K2 MKKS PRDX1
3 digestive/alimentary MP:0005381 9.65 CASP1 FURIN MAP2K2 PCSK6 TLR9
4 immune system MP:0005387 9.63 ANTXR1 ANTXR2 CASP1 FURIN PRDX1 TLR9
5 mortality/aging MP:0010768 9.61 ANTXR1 ANTXR2 CASP1 FURIN MAP2K2 MKKS
6 neoplasm MP:0002006 9.02 ANTXR1 CASP1 MAP2K2 PCSK6 PRDX1

Drugs & Therapeutics for Anthrax Disease

Drugs for Anthrax Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 54)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Diphenhydramine Approved, Investigational Phase 4 147-24-0, 58-73-1 3100
2
Promethazine Approved, Investigational Phase 4 60-87-7 4927
3
Histamine Approved, Investigational Phase 4,Phase 1 51-45-6, 75614-87-8 774
4 Immunologic Factors Phase 4,Phase 2,Phase 3,Phase 1
5 Vaccines Phase 4,Phase 3,Phase 2,Phase 1
6
Histamine Phosphate Phase 4,Phase 1 51-74-1 65513
7 Hypnotics and Sedatives Phase 4
8 Histamine H1 Antagonists Phase 4
9 Anti-Allergic Agents Phase 4
10 Anesthetics, Local Phase 4
11 Antibodies Phase 4,Phase 2,Phase 3,Phase 1
12 Antibodies, Monoclonal Phase 4,Phase 2,Phase 3,Phase 1
13 Neurotransmitter Agents Phase 4
14 Antiemetics Phase 4
15 Peripheral Nervous System Agents Phase 4
16 Histamine Antagonists Phase 4
17 Anesthetics Phase 4
18 Central Nervous System Depressants Phase 4
19 Gastrointestinal Agents Phase 4,Phase 2,Phase 1
20 Immunoglobulins Phase 4,Phase 2,Phase 3,Phase 1
21 Autonomic Agents Phase 4
22 Dermatologic Agents Phase 4
23 Antipruritics Phase 4
24 Antitoxins Phase 4,Phase 1,Phase 2
25 Antibodies, Blocking Phase 4
26
Citric Acid Approved, Nutraceutical, Vet_approved Phase 2, Phase 3,Phase 1 77-92-9 311
27
Glycine Approved, Nutraceutical, Vet_approved Phase 2, Phase 3 56-40-6 750
28 Citrate Phase 2, Phase 3,Phase 1
29
Glyburide Approved Phase 2 10238-21-8 3488
30
Aluminum hydroxide Approved, Investigational Phase 2,Phase 1 21645-51-2
31
Ciprofloxacin Approved, Investigational Phase 2,Phase 1 85721-33-1 2764
32
Imidacloprid Vet_approved Phase 2 105827-78-9 86418
33 Hypoglycemic Agents Phase 2
34 Antacids Phase 2,Phase 1
35 Adjuvants, Immunologic Phase 2,Phase 1
36 Anti-Ulcer Agents Phase 2,Phase 1
37 Immunoglobulins, Intravenous Phase 1, Phase 2
38 gamma-Globulins Phase 1, Phase 2
39 Rho(D) Immune Globulin Phase 1, Phase 2
40 Immunoglobulin G Phase 1, Phase 2
41 Anti-Infective Agents Phase 2,Phase 1
42 Cytochrome P-450 Enzyme Inhibitors Phase 2,Phase 1
43 Anti-Bacterial Agents Phase 2,Phase 1
44 Cytochrome P-450 CYP1A2 Inhibitors Phase 2,Phase 1
45 Topoisomerase Inhibitors Phase 2,Phase 1
46 Pharmaceutical Solutions Phase 2,Phase 1
47
Mannitol Approved, Investigational Phase 1 69-65-8 453 6251
48
Doxycycline Approved, Investigational, Vet_approved Phase 1 564-25-0 54671203
49
Diethylenetriamine Phase 1 111-40-0 8111
50 Antibiotics, Antitubercular Phase 1

Interventional clinical trials:

(show top 50) (show all 51)
# Name Status NCT ID Phase Drugs
1 CDC Anthrax Vaccine Clinical Trial Completed NCT00119067 Phase 4
2 Effect of Raxibacumab on Immunogenicity of Anthrax Vaccine Adsorbed Completed NCT02339155 Phase 4 Diphenhydramine
3 Assessment of the Immunogenicity and Safety of a Dose-Sparing BioThrax® AVA Schedule Completed NCT01641991 Phase 4
4 An Open Label Field Study of Anthim (Obiltoxaximab) in Subjects Exposed to B. Anthracis Not yet recruiting NCT03088111 Phase 4
5 Clinical Benefit, Safety and PK of Raxibacumab in Subjects Exposed to Bacillus Anthracis Not yet recruiting NCT02177721 Phase 4
6 Immunogenicity and Safety Study of a Three-Dose BioThrax® Regimen for Post-Exposure Prophylaxis in Healthy Adults Completed NCT01491607 Phase 3
7 An Open-label, Nonrandomized Study to Evaluate the Safety and Immunogenicity of Raxibacumab With Reinjection Completed NCT02016963 Phase 2, Phase 3
8 Glyburide Advantage in Malignant Edema and Stroke - Remedy Pharmaceuticals Unknown status NCT01794182 Phase 2 RP-1127 (Glyburide for Injection)
9 A Phase 2 Safety and Immunogenicity Study for an Anthrax Vaccine Using 3 Schedules and Two Dose Levels Completed NCT01770743 Phase 2
10 Safety, Tolerability and Immunogenicity of Recombinant Anthrax Vaccine Compared With Anthrax Vaccine Adsorbed Completed NCT00170469 Phase 2
11 Safety and Pharmacokinetics Study of Anthrax Immune Globulin Intravenous (AIGIV) Completed NCT00845650 Phase 1, Phase 2
12 Phase II Study of Range and Schedule of rPA Doses Completed NCT00170456 Phase 2
13 Ciprofloxacin BioThrax Co-Administration Study Completed NCT01753115 Phase 2 Ciprofloxacin
14 Trial of rPA-102 Vaccine in Healthy Adult Volunteers Completed NCT00100724 Phase 2
15 BARDA Securing Anthrax Immunity For the Elderly Recruiting NCT03518125 Phase 2 Sodium chloride injection USP, 0.9% (placebo)
16 A Study to Assess Dose-Response, Efficacy (Immunogenicity) and the Safety of GC1109 Suspended NCT01624532 Phase 2 Normal Saline
17 UMD rPA Regimen Trial in Adults Terminated NCT00133484 Phase 2
18 A Phase 1 Ascending Dose Study to Assess the Safety and Immunogenicity of Adenovirus Anthrax Vector Candidate Vaccines Completed NCT01979406 Phase 1
19 A New Anthrax Vaccine Administered by the Intramuscular (IM) Route in Healthy Adults Completed NCT00057525 Phase 1
20 Anthrax-rPA: Safety, Tolerability, Immunogenicity Completed NCT00063843 Phase 1
21 Anthrax Vaccine Clinical Trials Completed NCT00114621 Phase 1 Anthrax Vaccine
22 Safety and Pharmacokinetic Study of Anthrax Immune Globulin Derived From Human Serum Completed NCT00448253 Phase 1
23 Safety, Tolerability and Immunogenicity Study of AV7909 Anthrax Vaccine in Healthy Adults Completed NCT01263691 Phase 1 Control
24 A Study of Anthrax Vaccines Px563L and RPA563 in Healthy Adult Subjects Completed NCT02655549 Phase 1
25 Trial to Evaluate the Safety and Immunogenicity of an Anthrax Recombinant Protective Antigen Vaccine Completed NCT00103467 Phase 1
26 PA83-FhCMB Plant-Derived Recombinant Protective Antigen (rPA) Anthrax Vaccine Completed NCT02239172 Phase 1
27 Efficacy and Safety of Anthrax Vaccine, GC1109 Completed NCT01867957 Phase 1
28 Monoclonal Antibody for Treatment of Inhalation Anthrax Completed NCT00138411 Phase 1 Ciprofloxacin 500 mg;ETI-204 (Anthim)
29 Dose Escalation Study of Valortim® (MDX-1303) Administered Intravenously (IV) in Healthy, Normal Subjects Completed NCT01265745 Phase 1 Normal Saline for Injection
30 Single Dose, Weight-Based, Dose-Escalation Study With Intravenous ETI-204 in Adult Volunteers Completed NCT01453907 Phase 1 ETI-204, "Anthim";placebo
31 Safety and Pharmacokinetics Study of Human Monoclonal Antibody (AVP-21D9) Completed NCT01202695 Phase 1 AVP-21D9;Placebo
32 Open-Label, Randomized, Parallel Group Study to Assess the Safety, Tolerability and PK of ETI-204 Alone and in Presence of Ciprofloxacin in Adult Volunteers Completed NCT01952444 Phase 1
33 Safety, Tolerability, and PK of Single IM Doses of ETI-204 in Adult Volunteers Completed NCT01932437 Phase 1
34 Safety, Tolerability and PK of Repeat Administration of IV ETI-204 Completed NCT01932242 Phase 1
35 A Study to Assess the Safety, Tolerability and PK of a Single IV Dose of ETI-204 in Adult Volunteers Completed NCT01929226 Phase 1
36 Study of Valortim® (MDX-1303) and Its Selected Formulation Components Percutaneous Use Completed NCT01204866 Phase 1 Valortim and Selected Components
37 A Phase I Study of Safety and Immunogenicity of the WRAIR HIV-1 Vaccine Completed NCT00412477 Phase 1
38 NasoShield Study of Safety and Immunogenicity Active, not recruiting NCT03352466 Phase 1
39 Ph1 Study of Valortim and Ciprofloxacin in Humans Suspended NCT00964561 Phase 1 Ciprofloxacin and Valortim;Placebo Antibiotic and Valortim
40 Ph1 Study of Valortim and Doxycycline in Humans Terminated NCT00964834 Phase 1 Doxycycline and Valortim;Placebo Antibiotic and Valortim;Placebo Antibiotic and Placebo Valortim
41 Plasmapheresis of Anthrax-Vaccinated Subjects for Production of Anthrax Immune Globulin Completed NCT00031291 Anthrax Immune Globulin
42 Febrile Whole Blood Specimen Collection and Testing Completed NCT03498027
43 VHA Clinicians and Bioterror Events: Interactive Web-based Learning Completed NCT00123396 Not Applicable
44 Special Drug Use Investigation of Ciproxan Injection in Pediatrics Completed NCT02555059 Cipro (Ciprofloxacin, BAYQ3939)
45 Ciprofloxacin Special Drug Use Investigation - To Investigate the Safety and Efficacy in Patients With Ciprofloxacin iv Administration Without Dilution Completed NCT01690559 Cipro (Ciprofloxacin, BAYQ3939)
46 Assessment of the Safety and Efficacy of Ciproxan-I.V. in Daily Clinical Practice - Analysis Results From a Post-marketing Surveillance Completed NCT01670435 Ciprofloxacin (BAYQ3939)
47 Natural History of Anthrax: a Study of Primary Infected, Recovered, and Exposed Individuals (SPoRE); and Evaluation of AVA-Vaccinated Recipients Recruiting NCT00050310
48 BioThrax® (Anthrax) Vaccine in Pregnancy Registry Recruiting NCT01653392
49 Admission and Management of Occupational or Other Exposures to Biodefense/Bioterrorism Agents or to Epidemic/Emerging Infectious Diseases Recruiting NCT01200953
50 A Field Study Evaluating Clinical Benefit and Safety of AIGIV (ANTHRASIL®) in Inhalational Anthrax Patients Not yet recruiting NCT03569553 AIGIV

Search NIH Clinical Center for Anthrax Disease

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Cochrane evidence based reviews: anthrax

Genetic Tests for Anthrax Disease

Anatomical Context for Anthrax Disease

MalaCards organs/tissues related to Anthrax Disease:

41
Lung, Skin, Lymph Node, Testes, Myeloid, Endothelial, T Cells

The Foundational Model of Anatomy Ontology organs/tissues related to Anthrax Disease:

19
Skin, Lung Lymph Nodes Or

Publications for Anthrax Disease

Articles related to Anthrax Disease:

(show top 50) (show all 820)
# Title Authors Year
1
Anthrax biomarker: An ultrasensitive fluorescent ratiometry of dipicolinic acid by using terbium(III)-modified carbon dots. ( 30262082 )
2019
2
An Optimal Control Model to Reduce and Eradicate Anthrax Disease in Herbivorous Animals. ( 30357598 )
2018
3
Quantitative Prediction of Multivalent Ligand-Receptor Binding Affinities for Influenza, Cholera, and Anthrax Inhibition. ( 29474056 )
2018
4
Constructing and transient expression of a gene cassette containing edible vaccine elements and shigellosis, anthrax and cholera recombinant antigens in tomato. ( 30244396 )
2018
5
Two cases of human cutaneous anthrax with massive tissue damage, severe edema, and slight injury to the liver. ( 29231245 )
2018
6
Obiltoxaximab (Anthim) for inhalation anthrax. ( 30383733 )
2018
7
Treating Anthrax-Induced Meningitis in Rabbits. ( 29661872 )
2018
8
A Bacteriophage T4 Nanoparticle-Based Dual Vaccine against Anthrax and Plague. ( 30327445 )
2018
9
Validated MALDI-TOF-MS method for anthrax lethal factor provides early diagnosis and evaluation of therapeutics. ( 29224733 )
2018
10
The Case for Human Serum as a Highly Preferable Sample Matrix for Detection of Anthrax Toxins. ( 30350950 )
2018
11
Temporal patterns of anthrax outbreaks among livestock in Lesotho, 2005-2016. ( 30356323 )
2018
12
A case of anthrax in two captive pumas (Puma concolor). ( 30369586 )
2018
13
Structural basis for anthrax toxin receptor 1 recognition by Seneca Valley Virus. ( 30381454 )
2018
14
Effect of late endosomal DOBMP lipid and traditional model lipids of electrophysiology on the anthrax toxin channel activity. ( 30409515 )
2018
15
Design and use of a novel substrate for simple, rapid, and specific early detection of anthrax infection. ( 30412638 )
2018
16
Medical Spending for the 2001 Anthrax Letter Attacks. ( 30417803 )
2018
17
Anthrax Exposure, Belief in Exposure, and Postanthrax Symptoms Among Survivors of a Bioterrorist Attack on Capitol Hill. ( 30417804 )
2018
18
Immunogenicity of anthrax recombinant peptides and killed spores in goats and protective efficacy of immune sera in A/J mouse model. ( 30446695 )
2018
19
Spatio-temporal epidemiology of anthrax in Hippopotamus amphibious in Queen Elizabeth Protected Area, Uganda. ( 30485342 )
2018
20
Seneca Valley virus attachment and uncoating mediated by its receptor anthrax toxin receptor 1. ( 30514821 )
2018
21
Human monoclonal anti-protective antigen antibody for the low-dose post-exposure prophylaxis and treatment of Anthrax. ( 30526504 )
2018
22
A niosome formulation modulates the Th1/Th2 bias immune response in mice and also provides protection against anthrax spore challenge. ( 30532531 )
2018
23
Closed Genome Sequence Obtained Using Hybrid Nanopore/Illumina Assembly of a Bacillus anthracis Isolate from an Animal-Skin-Drum-Associated Anthrax Case in the United Kingdom. ( 30533686 )
2018
24
Decoupling environmental effects and host population dynamics for anthrax, a classic reservoir-driven disease. ( 30540815 )
2018
25
Evaluation of in vitro antimicrobial susceptibility of Bacillus anthracis strains isolated during anthrax outbreaks in Italy from 1984 to 2017. ( 30541185 )
2018
26
DUST-BATHING BEHAVIORS OF AFRICAN HERBIVORES AND THE POTENTIAL RISK OF INHALATIONAL ANTHRAX. ( 29053428 )
2018
27
Ratiometric fluorescence detection of an anthrax biomarker with Eu3+-chelated chitosan biopolymers. ( 29103500 )
2018
28
Small molecule inhibitors of anthrax edema factor. ( 29198864 )
2018
29
Galactosylation of the Secondary Cell Wall Polysaccharide of Bacillus anthracis and Its Contribution to Anthrax Pathogenesis. ( 29229702 )
2018
30
Anthrax outbreaks in the humans - livestock and wildlife interface areas of Northern Tanzania: a retrospective record review 2006-2016. ( 29304765 )
2018
31
Ecological suitability modeling for anthrax in the Kruger National Park, South Africa. ( 29377918 )
2018
32
Terbium Functionalized Micelle Nanoprobe for Ratiometric Fluorescence Detection of Anthrax Spore Biomarker. ( 29385798 )
2018
33
Spore concentration and modified host resistance as cause of anthrax outbreaks: A practitioner's perspective. ( 29386683 )
2018
34
An investigation of the pH dependence of copper-substituted anthrax lethal factor and its mechanistic implications. ( 29407865 )
2018
35
Role of the Antigen Capture Pathway in the Induction of a Neutralizing Antibody Response to Anthrax Protective Antigen. ( 29487236 )
2018
36
Generation and screening of efficient neutralizing single domain antibodies (VHHs) against the critical functional domain of anthrax protective antigen (PA). ( 29524493 )
2018
37
Injectional anthrax in human: A new face of the old disease. ( 29533547 )
2018
38
Does anthrax antitoxin therapy have a role in the treatment of inhalational anthrax? ( 29570493 )
2018
39
Inhibition of anthrax lethal factor by ssDNA aptamers. ( 29580944 )
2018
40
Ratiometric fluorometric determination of the anthrax biomarker 2,6-dipicolinic acid by using europium(III)-doped carbon dots in a test stripe. ( 29594713 )
2018
41
Nanoporous Hydrogels for the Observation of Anthrax Exotoxin Translocation Dynamics. ( 29595948 )
2018
42
A Dual Role for the Bacillus anthracis Master Virulence Regulator AtxA: Control of Sporulation and Anthrax Toxin Production. ( 29599764 )
2018
43
Spore concentration and modified host resistance as a cause of anthrax outbreaks - A comment. ( 29608180 )
2018
44
Certhrax Is an Antivirulence Factor for the Anthrax-Like Organism Bacillus cereus Strain G9241. ( 29610258 )
2018
45
Trimethyl Chitosan Nanoparticles Encapsulated Protective Antigen Protects the Mice Against Anthrax. ( 29616046 )
2018
46
Perturbing Tandem Energy Transfer in Luminescent Heterobinuclear Lanthanide Coordination Polymer Nanoparticles Enables Real-Time Monitoring of Release of the Anthrax Biomarker from Bacterial Spores. ( 29701058 )
2018
47
Spores and soil from six sides: interdisciplinarity and the environmental biology of anthrax (Bacillus anthracis). ( 29732670 )
2018
48
Correction to A Chemically Synthesized Capture Agent Enables the Selective, Sensitive, and Robust Electrochemical Detection of Anthrax Protective Antigen. ( 29749728 )
2018
49
Bioinspired detoxification of blood: The efficient removal of anthrax toxin protective antigen using an extracorporeal macroporous adsorbent device. ( 29760471 )
2018
50
Molecular Investigation of an Anthrax Epidemic in Guizhou Province, China. ( 29786054 )
2018

Variations for Anthrax Disease

Expression for Anthrax Disease

Search GEO for disease gene expression data for Anthrax Disease.

Pathways for Anthrax Disease

Pathways related to Anthrax Disease according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.51 ANTXR1 ANTXR2 CASP1 MAP2K2 TLR9
2
Show member pathways
12.31 CASP1 FURIN MAP2K2 TLR9
3
Show member pathways
12.14 CASP1 MAP2K2 TLR9
4
Show member pathways
11.78 CASP1 MAP2K2 TLR9
5
Show member pathways
11.15 ANTXR1 ANTXR2 FURIN MAP2K2
6
Show member pathways
11.1 FURIN PCSK6
7 10.27 ANTXR1 ANTXR2 CASP1 MAP2K2
8
Show member pathways
9.85 FURIN PCSK6

GO Terms for Anthrax Disease

Cellular components related to Anthrax Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 endoplasmic reticulum GO:0005783 9.55 ANTXR2 FURIN MAP2K2 PCSK6 TLR9
2 cell surface GO:0009986 9.26 ANTXR1 ANTXR2 FURIN PCSK6
3 endosome membrane GO:0010008 8.92 ANTXR1 ANTXR2 FURIN TLR9

Biological processes related to Anthrax Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 determination of left/right symmetry GO:0007368 9.46 MKKS PCSK6
2 protein processing GO:0016485 9.43 FURIN PCSK6
3 toxin transport GO:1901998 9.4 ANTXR1 ANTXR2
4 peptide hormone processing GO:0016486 9.37 FURIN PCSK6
5 reproductive process GO:0022414 9.32 ANTXR1 ANTXR2
6 secretion by cell GO:0032940 9.26 FURIN PCSK6
7 regulation of lipoprotein lipase activity GO:0051004 9.16 FURIN PCSK6
8 regulation of stress-activated MAPK cascade GO:0032872 8.96 MAP2K2 PRDX1
9 nerve growth factor production GO:0032902 8.62 FURIN PCSK6

Molecular functions related to Anthrax Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 transmembrane signaling receptor activity GO:0004888 9.33 ANTXR1 ANTXR2 TLR9
2 endopeptidase activity GO:0004175 9.13 CASP1 FURIN PCSK6
3 nerve growth factor binding GO:0048406 8.62 FURIN PCSK6

Sources for Anthrax Disease

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....